PHPB ameliorates memory deficits and reduces oxidative injury in Alzheimer’s disease mouse model by activating Nrf2 signaling pathway
Acta Pharmacologica Sinica, Published online: 26 February 2024; doi:10.1038/s41401-024-01240-9PHPB ameliorates memory deficits and reduces oxidative injury in Alzheimer’s disease mouse model by activating Nrf2 signaling pathway (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - February 26, 2024 Category: Drugs & Pharmacology Authors: Nian-ying Shang Long-jian Huang Jia-qi Lan Yu-ying Kang Jing-shu Tang Hong-yue Wang Xin-nan Li Zhuo Sun Qiu-yu Chen Meng-yao Liu Zi-peng Wen Xin-hong Feng Lei Wu Ying Peng Source Type: research
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
In this study we conducted HDACi-perturbated proteomics and phosphoproteomics analyses in HDACi-sensitive and -resistant cell lines using a tandem mass tag (TMT)-based quantitative proteomic strategy. We found that the ribosome biogenesis proteins MRTO4, PES1, WDR74 and NOP16 vital to tumorigenesis might regulate the tumor sensitivity to HDACi. By integrating HDACi-perturbated protein signature with previously reported proteomics and drug sensitivity data, we predicted and validated a series of drug combination pairs potentially to enhance the sensitivity of HDACi in diverse solid tumor. Functional phosphoproteomic analysi...
Source: Acta Pharmacologica Sinica - February 21, 2024 Category: Drugs & Pharmacology Authors: Bing-Bing Hao Ke Ma Jun-Yu Xu Ru-Feng Fan Wen-Si Zhao Xing-Long Jia Lin-Hui Zhai SangKyu Lee Dong Xie Min-Jia Tan Source Type: research
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
In this study we conducted HDACi-perturbated proteomics and phosphoproteomics analyses in HDACi-sensitive and -resistant cell lines using a tandem mass tag (TMT)-based quantitative proteomic strategy. We found that the ribosome biogenesis proteins MRTO4, PES1, WDR74 and NOP16 vital to tumorigenesis might regulate the tumor sensitivity to HDACi. By integrating HDACi-perturbated protein signature with previously reported proteomics and drug sensitivity data, we predicted and validated a series of drug combination pairs potentially to enhance the sensitivity of HDACi in diverse solid tumor. Functional phosphoproteomic analysi...
Source: Acta Pharmacologica Sinica - February 21, 2024 Category: Drugs & Pharmacology Authors: Bing-Bing Hao Ke Ma Jun-Yu Xu Ru-Feng Fan Wen-Si Zhao Xing-Long Jia Lin-Hui Zhai SangKyu Lee Dong Xie Min-Jia Tan Source Type: research
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
In this study we conducted HDACi-perturbated proteomics and phosphoproteomics analyses in HDACi-sensitive and -resistant cell lines using a tandem mass tag (TMT)-based quantitative proteomic strategy. We found that the ribosome biogenesis proteins MRTO4, PES1, WDR74 and NOP16 vital to tumorigenesis might regulate the tumor sensitivity to HDACi. By integrating HDACi-perturbated protein signature with previously reported proteomics and drug sensitivity data, we predicted and validated a series of drug combination pairs potentially to enhance the sensitivity of HDACi in diverse solid tumor. Functional phosphoproteomic analysi...
Source: Acta Pharmacologica Sinica - February 21, 2024 Category: Drugs & Pharmacology Authors: Bing-Bing Hao Ke Ma Jun-Yu Xu Ru-Feng Fan Wen-Si Zhao Xing-Long Jia Lin-Hui Zhai SangKyu Lee Dong Xie Min-Jia Tan Source Type: research
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
In this study we conducted HDACi-perturbated proteomics and phosphoproteomics analyses in HDACi-sensitive and -resistant cell lines using a tandem mass tag (TMT)-based quantitative proteomic strategy. We found that the ribosome biogenesis proteins MRTO4, PES1, WDR74 and NOP16 vital to tumorigenesis might regulate the tumor sensitivity to HDACi. By integrating HDACi-perturbated protein signature with previously reported proteomics and drug sensitivity data, we predicted and validated a series of drug combination pairs potentially to enhance the sensitivity of HDACi in diverse solid tumor. Functional phosphoproteomic analysi...
Source: Acta Pharmacologica Sinica - February 21, 2024 Category: Drugs & Pharmacology Authors: Bing-Bing Hao Ke Ma Jun-Yu Xu Ru-Feng Fan Wen-Si Zhao Xing-Long Jia Lin-Hui Zhai SangKyu Lee Dong Xie Min-Jia Tan Source Type: research
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
In this study we conducted HDACi-perturbated proteomics and phosphoproteomics analyses in HDACi-sensitive and -resistant cell lines using a tandem mass tag (TMT)-based quantitative proteomic strategy. We found that the ribosome biogenesis proteins MRTO4, PES1, WDR74 and NOP16 vital to tumorigenesis might regulate the tumor sensitivity to HDACi. By integrating HDACi-perturbated protein signature with previously reported proteomics and drug sensitivity data, we predicted and validated a series of drug combination pairs potentially to enhance the sensitivity of HDACi in diverse solid tumor. Functional phosphoproteomic analysi...
Source: Acta Pharmacologica Sinica - February 21, 2024 Category: Drugs & Pharmacology Authors: Bing-Bing Hao Ke Ma Jun-Yu Xu Ru-Feng Fan Wen-Si Zhao Xing-Long Jia Lin-Hui Zhai SangKyu Lee Dong Xie Min-Jia Tan Source Type: research
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
Acta Pharmacologica Sinica, Published online: 21 February 2024; doi:10.1038/s41401-024-01236-5Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - February 21, 2024 Category: Drugs & Pharmacology Authors: Bing-bing Hao Ke Ma Jun-yu Xu Ru-feng Fan Wen-si Zhao Xing-long Jia Lin-hui Zhai SangKyu Lee Dong Xie Min-jia Tan Source Type: research
Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities
Acta Pharmacol Sin. 2024 Feb 15. doi: 10.1038/s41401-024-01232-9. Online ahead of print.ABSTRACTHER2-positive (HER2+) metastatic breast cancer (mBC) is highly aggressive and a major threat to human health. Despite the significant improvement in patients' prognosis given the drug development efforts during the past several decades, many clinical questions still remain to be addressed such as efficacy when combining different therapeutic modalities, best treatment sequences, interindividual variability as well as resistance and potential coping strategies. To better answer these questions, we developed a mechanistic quantita...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Ya-Ting Zhou Jia-Hui Chu Shu-Han Zhao Ge-Li Li Zi-Yi Fu Su-Jie Zhang Xue-Hu Gao Wen Ma Kai Shen Yuan Gao Wei Li Yong-Mei Yin Chen Zhao Source Type: research
Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient
In this study, we systematically explored the validity of sequential ALK inhibitors (alectinib, lorlatinib, crizotinib, ceritinib and brigatinib) for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models. Based on the patient-derived models and clinical responses of the patient, we found that crizotinib might inhibit proliferation of EML4-ALK positive tumors resistant to alectinib and lorlatinib. In addition, NSCLC patients harboring the G1269A mutation, which was identified in alectinib, lorlatinib and crizotinib-resistant NSCLC, showed resp...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Fu-Jing Ge Xiao-Yang Dai Yao Qiu Xiang-Ning Liu Chen-Ming Zeng Xiao-Yuan Xu Yi-Dan Chen Hong Zhu Qiao-Jun He Ren-Hua Gai Sheng-Lin Ma Xue-Qin Chen Bo Yang Source Type: research
Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities
Acta Pharmacol Sin. 2024 Feb 15. doi: 10.1038/s41401-024-01232-9. Online ahead of print.ABSTRACTHER2-positive (HER2+) metastatic breast cancer (mBC) is highly aggressive and a major threat to human health. Despite the significant improvement in patients' prognosis given the drug development efforts during the past several decades, many clinical questions still remain to be addressed such as efficacy when combining different therapeutic modalities, best treatment sequences, interindividual variability as well as resistance and potential coping strategies. To better answer these questions, we developed a mechanistic quantita...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Ya-Ting Zhou Jia-Hui Chu Shu-Han Zhao Ge-Li Li Zi-Yi Fu Su-Jie Zhang Xue-Hu Gao Wen Ma Kai Shen Yuan Gao Wei Li Yong-Mei Yin Chen Zhao Source Type: research
Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient
In this study, we systematically explored the validity of sequential ALK inhibitors (alectinib, lorlatinib, crizotinib, ceritinib and brigatinib) for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models. Based on the patient-derived models and clinical responses of the patient, we found that crizotinib might inhibit proliferation of EML4-ALK positive tumors resistant to alectinib and lorlatinib. In addition, NSCLC patients harboring the G1269A mutation, which was identified in alectinib, lorlatinib and crizotinib-resistant NSCLC, showed resp...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Fu-Jing Ge Xiao-Yang Dai Yao Qiu Xiang-Ning Liu Chen-Ming Zeng Xiao-Yuan Xu Yi-Dan Chen Hong Zhu Qiao-Jun He Ren-Hua Gai Sheng-Lin Ma Xue-Qin Chen Bo Yang Source Type: research
Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities
Acta Pharmacol Sin. 2024 Feb 15. doi: 10.1038/s41401-024-01232-9. Online ahead of print.ABSTRACTHER2-positive (HER2+) metastatic breast cancer (mBC) is highly aggressive and a major threat to human health. Despite the significant improvement in patients' prognosis given the drug development efforts during the past several decades, many clinical questions still remain to be addressed such as efficacy when combining different therapeutic modalities, best treatment sequences, interindividual variability as well as resistance and potential coping strategies. To better answer these questions, we developed a mechanistic quantita...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Ya-Ting Zhou Jia-Hui Chu Shu-Han Zhao Ge-Li Li Zi-Yi Fu Su-Jie Zhang Xue-Hu Gao Wen Ma Kai Shen Yuan Gao Wei Li Yong-Mei Yin Chen Zhao Source Type: research
Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient
In this study, we systematically explored the validity of sequential ALK inhibitors (alectinib, lorlatinib, crizotinib, ceritinib and brigatinib) for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models. Based on the patient-derived models and clinical responses of the patient, we found that crizotinib might inhibit proliferation of EML4-ALK positive tumors resistant to alectinib and lorlatinib. In addition, NSCLC patients harboring the G1269A mutation, which was identified in alectinib, lorlatinib and crizotinib-resistant NSCLC, showed resp...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Fu-Jing Ge Xiao-Yang Dai Yao Qiu Xiang-Ning Liu Chen-Ming Zeng Xiao-Yuan Xu Yi-Dan Chen Hong Zhu Qiao-Jun He Ren-Hua Gai Sheng-Lin Ma Xue-Qin Chen Bo Yang Source Type: research
Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities
Acta Pharmacol Sin. 2024 Feb 15. doi: 10.1038/s41401-024-01232-9. Online ahead of print.ABSTRACTHER2-positive (HER2+) metastatic breast cancer (mBC) is highly aggressive and a major threat to human health. Despite the significant improvement in patients' prognosis given the drug development efforts during the past several decades, many clinical questions still remain to be addressed such as efficacy when combining different therapeutic modalities, best treatment sequences, interindividual variability as well as resistance and potential coping strategies. To better answer these questions, we developed a mechanistic quantita...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Ya-Ting Zhou Jia-Hui Chu Shu-Han Zhao Ge-Li Li Zi-Yi Fu Su-Jie Zhang Xue-Hu Gao Wen Ma Kai Shen Yuan Gao Wei Li Yong-Mei Yin Chen Zhao Source Type: research
Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient
In this study, we systematically explored the validity of sequential ALK inhibitors (alectinib, lorlatinib, crizotinib, ceritinib and brigatinib) for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models. Based on the patient-derived models and clinical responses of the patient, we found that crizotinib might inhibit proliferation of EML4-ALK positive tumors resistant to alectinib and lorlatinib. In addition, NSCLC patients harboring the G1269A mutation, which was identified in alectinib, lorlatinib and crizotinib-resistant NSCLC, showed resp...
Source: Acta Pharmacologica Sinica - February 15, 2024 Category: Drugs & Pharmacology Authors: Fu-Jing Ge Xiao-Yang Dai Yao Qiu Xiang-Ning Liu Chen-Ming Zeng Xiao-Yuan Xu Yi-Dan Chen Hong Zhu Qiao-Jun He Ren-Hua Gai Sheng-Lin Ma Xue-Qin Chen Bo Yang Source Type: research
